Event

10

February 2020

Psychedelics in Business

11:30am-1:30pm | Fairmont Royal York - 100 Front Street West, Toronto

In a fast paced and rapidly changing economy – creativity, innovation, and performance optimization are among the top goals of today’s modern business leaders. Could this be a new trend that many Canadian businesspeople are adopting? What are the keys to unlocking psilocybin’s medical value? What does the market potential look like? What is microdosing? Could the next boom following cannabis be psychedelics? How does it work and what are the potential mental health and business benefits? How does the research play a role? What does the data suggest? What’s the role of government? In this Economic Club of Canada exclusive, our distinguished panel will explore all this and more.

- Lunch will be served -

Member price:
Individual seat: $89 +HST
Table (seats 10): $800 +HST

Regular price:
Individual seat: $110 +HST
Table (seats 10): $990 +HST

Important:
- For information about accessibility, please email jacqui@economicclub.ca
- Dietary restriction notes and meal requests must be submitted jacqui@economicclub.ca.
- Refunds/credits: We require three business days notice in advance of the event date for ticket cancellations

*The views expressed on the Economic Club platform are not that of the Economic Club or its affiliates but of the speakers alone and the organizations they represent*

Psychedelics in Business

Bruce Linton

ENTREPRENEUR, INVESTOR AND BUSINESS LEADER

Bruce Linton

FOUNDER & FORMER CHAIRMAN, CEO AND CO-CEO OF CANOPY GROWTH CORPORATION (CGC) FORMERLY TWEED MARIJUANA INCORPORATED, A CANNABIS COMPANY BASED IN SMITHS FALLS, ONTARIO, CANADA. BRUCE FOUNDED TWEED IN 2013 AND RENAMED IT CANOPY GROWTH CORPORATION IN 2015. CANOPY GROWTH CORPORATION WAS THE FIRST CANNABIS COMPANY IN NORTH AMERICA TO BE LISTED ON A MAJOR STOCK EXCHANGE (TSX-V IN APRIL 2014 AND TSX IN JULY 2016) AND TO BE INCLUDED ON A MAJOR STOCK INDEX (S&P/TSX COMPOSITE INDEX IN MARCH 2017). BRUCE LED CGC FROM A TSX-V LISTED START-UP COMPANY WITH AN $80 MILLION MARKET CAP TO A NYSE/TSX LISTED COMPANY (S&P/TSX60) INCLUDING MORE THAN 30 M&A ACTIVITIES. RANKING NUMBER ONE ON THE TSX30 WITH A MARKET CAP OF OVER $20 BILLION BY THE SUMMER OF 2019. 

BRUCE’S EXPERIENCE AS A FOUNDER, CEO, AND BOARD MEMBER ACROSS A DIVERSITY OF SECTORS WAS A HUGE INFLUENCE FOR THE SUCCESS OF CANOPY GROWTH CORPORATION. EARNING MARKET SUPPORT FOR CAPITAL RAISES OF OVER $6 BILLION IN PUBLIC CAPITAL MARKETS AND PRIVATE PLACEMENTS, THE COMPANY FUNDED CAPACITY GROWTH AND OPENED NEW MARKETS, INCLUDING A $5 BILLION CAD INVESTMENT BY FORTUNE 500 BEVERAGE COMPANY, CONSTELLATION BRANDS (NYSE:STZ).

BRUCE IS CO-FOUNDER AND WAS CHAIRMAN AND CEO OF CANOPY RIVERS, INC.(TSX:RIV)

Dr. Tara Elton-Marshall

Independent Scientist at the Institute for Mental Health Policy Research at CAMH

Dr. Tara Elton-Marshall

Dr. Elton-Marshall is an Independent Scientist at the Institute for Mental Health Policy Research at CAMH. She is a Co-Head of the Population Health and Community Transformation (PHACT) section in IMHPR, and the Co-Principal Investigator of the CAMH Monitor, and the Ontario Student Drug Use and Health Survey (OSDUHS). OSDUHS is a provincially representative school-based survey of adolescents in Ontario and the longest ongoing school survey in Canada (since 1977). The CAMH Monitor is a provincially representative survey of adults (18 and older) in Ontario. Both surveys examine drug use and mental health. She is also a Co-PI on the Ontario Node of the Canadian Research Initiative in Substance Misuse (CRISM), a strategic initiative funded by CIHR. CRISM is a national network of researchers, service providers, policy makers and people with lived experience across Canada. The goal is to conduct and translate evidence-based interventions for substance use to improve the health care system.

Dr. Elton-Marshall’s research evaluates addiction and substance use-related policies and programs with the goal of providing the evidence needed to strengthen future policy and programming and thus reduce addiction and substance use problems.

Ronan Levy

Executive Chairman
Field Trip Psychedelics Inc.

Ronan Levy

An entrepreneur and a visionary, Ronan is one the founders of Field Trip. Concurrent with his work at Field Trip, he is a partner at Grassfed Ventures, a venture capital and advisory firm focused on the cannabis and biotech industries and is a Member of the Board of Directors for Trait Biosciences Inc., a leading biotech company in the hemp and cannabis industries. Prior to his current roles, Ronan (along with Joseph, Hannan and Ryan) co-founded Canadian Cannabis Clinics and CanvasRx Inc., the latter of which was acquired by Aurora Cannabis Inc. (NYSE: ACB) in 2016, after which he served as Senior Vice President, Business and Corporate Affairs for Aurora. A lawyer by training, Ronan started his career as a corporate lawyer at Blake, Cassels Graydon LLP and Legal Counsel at CTVglobemedia Inc. (now Bell Media Inc.) He holds a Juris Doctor and a Bachelor of Commerce degree, both from the University of Toronto.

Rotem Petranker

Associate Director of the Psychedelic Studies Research Program
University of Toronto

Rotem Petranker

Rotem is a clinical psychology PhD student at York University, Toronto. He is also the Associate Director of the Psychedelic Studies Research Program at the University of Toronto and the director and co-founder of the Toronto Centre for Psychedelic Science. He has co-authored papers on the empirical and theoretical significance of microdosing psychedelics, as well as work on facial recognition, attention, mindfulness, and boredom. Rotem is a proponent of Open Science and is interested in improving the quality of science in general and especially in the nascent field of psychedelics.

Our Sponsors

Telus Interac Green Shield Canada